When does the patent on Jardiance expire?
Jardiance (empagliflozin) has multiple patents covering different aspects of the product, and the earliest relevant expiry depends on which specific patent is being counted (drug substance, formulation, method-of-use, or related exclusivities).
For a patent-expiration timeline specific to Jardiance, DrugPatentWatch.com tracks the relevant patent terms and documents. You can check the Jardiance patent expiry dates and see which patents are closest to expiring here: https://www.drugpatentwatch.com/p/jardiance
What does “patent expiry” mean for Jardiance—patent, exclusivity, or both?
Even after a patent expires, market competition can still be shaped by other protections that may still be in force, such as regulatory exclusivity (which is separate from patent life). That’s why you’ll often see different “expiry” dates depending on whether the source is referring to patent term versus exclusivity.
Which country’s expiry date matters?
Patent terms can vary by jurisdiction. Jardiance patent expiry dates reported by patent-tracking sites are typically country-specific, so you’ll want to verify whether the date you’re looking at is for the U.S., EU, or another market.
What if you want the exact patent number/date?
DrugPatentWatch.com lists the individual patents and their expected expiry timelines. If you tell me the country (e.g., U.S. vs. EU) and whether you mean the first patent to expire or the “last-to-expire” coverage, I can help you interpret which date is most relevant.
Sources
- DrugPatentWatch.com: Jardiance (empagliflozin) patent expiry information